Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors

被引:11
|
作者
Jaracz-Ros, Agnieszka [1 ]
Bernadat, Guillaume [2 ]
Cutolo, Pasquale [1 ]
Gallego, Carmen [1 ]
Gustavsson, Martin [3 ,8 ]
Cecon, Erika [4 ]
Baleux, Francoise [5 ]
Kufareva, Irina [3 ]
Handel, Tracy M. [3 ]
Bachelerie, Francoise [1 ]
Levoye, Angelique [6 ,7 ]
机构
[1] Univ Paris Saclay, INSERM, Inflammat Microbiome & Immunosurveillance, Clamart, France
[2] Univ Paris Saclay, CNRS, BioCIS, Chatenay Malabry, France
[3] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Jolla, CA USA
[4] Univ Paris, CNRS, INSERM, Inst Cochin, Paris, France
[5] Inst Pasteur, Unite Chim Biomol, Paris, France
[6] Univ Paris, INSERM, PARCC, Paris, France
[7] Univ Sorbonne Paris Nord, Bobigny, France
[8] Univ Copenhagen, Dept Biomed Sci, Blegdamsvej 3, Copenhagen 2200, Denmark
关键词
ACKR3; chemokine variants; CXCL12; CXCR4; GPCR signaling; pluridimensional efficacy; BETA-ARRESTIN; MOLECULAR-DYNAMICS; TUMOR-GROWTH; FACTOR-I; MIGRATION; ACTIVATION; DISSOCIATION; INHIBITION; REVEALS; AGONIST;
D O I
10.1002/JLB.2MA0320-383RR
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Chemokines play critical roles in numerous physiologic and pathologic processes through their action on seven-transmembrane (TM) receptors. The N-terminal domain of chemokines, which is a key determinant of signaling via its binding within a pocket formed by receptors' TM helices, can be the target of proteolytic processing. An illustrative case of this regulatory mechanism is the natural processing of CXCL12 that generates chemokine variants lacking the first two N-terminal residues. Whereas such truncated variants behave as antagonists of CXCR4, the canonical G protein-coupled receptor of CXCL12, they are agonists of the atypical chemokine receptor 3 (ACKR3/CXCR7), suggesting the implication of different structural determinants in the complexes formed between CXCL12 and its two receptors. Recent analyses have suggested that the CXCL12 N-terminus first engages the TM helices of ACKR3 followed by the receptor N-terminus wrapping around the chemokine core. Here we investigated the first stage of ACKR3-CXCL12 interactions by comparing the activity of substituted or N-terminally truncated variants of CXCL12 toward CXCR4 and ACKR3. We showed that modification of the first two N-terminal residues of the chemokine (K1R or P2G) does not alter the ability of CXCL12 to activate ACKR3. Our results also identified the K1R variant as a G protein-biased agonist of CXCR4. Comparative molecular dynamics simulations of the complexes formed by ACKR3 either with CXCL12 or with the P2G variant identified interactions between the N-terminal 2-4 residues of CXCL12 and a pocket formed by receptor's TM helices 2, 6, and 7 as critical determinants for ACKR3 activation.
引用
收藏
页码:1123 / 1135
页数:13
相关论文
共 50 条
  • [1] Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12
    del Barrio, Irene del Molino
    Wilkins, Georgina C.
    Meeson, Annette
    Ali, Simi
    Kirby, John A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [2] The CXCL12/CXCR4/ACKR3 Signaling Axis Regulates PKM2 and Glycolysis
    Luker, Kathryn E.
    Luker, Gary D.
    CELLS, 2022, 11 (11)
  • [3] The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting
    Smit, Martine J.
    Schlecht-Louf, Geraldine
    Neves, Maria
    van den Bor, Jelle
    Penela, Petronila
    Siderius, Marco
    Bachelerie, Francoise
    Mayor, Federico, Jr.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 541 - 563
  • [4] CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma
    Rusetska, Natalia
    Kowalski, Kamil
    Zalewski, Kamil
    Zieba, Sebastian
    Bidzinski, Mariusz
    Goryca, Krzysztof
    Kotowicz, Beata
    Fuksiewicz, Malgorzata
    Kopczynski, Janusz
    Bakula-Zalewska, Elwira
    Kowalik, Artur
    Kowalewska, Magdalena
    JOURNAL OF CLINICAL PATHOLOGY, 2022, 75 (05) : 324 - 332
  • [5] Dual Targeting of the Chemokine Receptors CXCR4 and ACKR3 with Novel Engineered Chemokines
    Hanes, Melinda S.
    Salanga, Catherina L.
    Chowdry, Arnab B.
    Comerford, Iain
    McColl, Shaun R.
    Kufareva, Irina
    Handel, Tracy M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (37) : 22385 - 22397
  • [6] The CXCL12/CXCR4/ACKR3 Response Axis in Chronic Neurodegenerative Disorders of the Central Nervous System: Therapeutic Target and Biomarker
    Yan, Yudie
    Su, Jingtong
    Zhang, Zhen
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2022, 42 (07) : 2147 - 2156
  • [7] Regulation of the chemokine receptors CXCR4 and ACKR3 by receptor activity-modifying proteins
    Pfersdorf, Fabian
    Romanazzi, Lucas
    Rosenkilde, Mette Marie
    Gustavsson, Martin
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2025, 301 (01)
  • [8] DPP4-Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence
    Elmansi, Ahmed M.
    Eisa, Nada H.
    Periyasamy-Thandavan, Sudharsan
    Kondrikova, Galina
    Kondrikov, Dmitry
    Calkins, Maggie M.
    Aguilar-Perez, Alexandra
    Chen, Jie
    Johnson, Maribeth
    Shi, Xing-ming
    Reitman, Charles
    McGee-Lawrence, Meghan E.
    Crawford, Kyler S.
    Dwinell, Michael B.
    Volkman, Brian F.
    Blumer, Joe B.
    Luttrell, Louis M.
    McCorvy, John D.
    Hill, William D.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (01) : 22 - 39
  • [9] The CXCL12/CXCR4/ACKR3 Response Axis in Chronic Neurodegenerative Disorders of the Central Nervous System: Therapeutic Target and Biomarker
    Yudie Yan
    Jingtong Su
    Zhen Zhang
    Cellular and Molecular Neurobiology, 2022, 42 : 2147 - 2156
  • [10] The chemokines CCL5 and CXCL12 exhibit high-affinity binding to N-terminal peptides of the non-cognate receptors CXCR4 and CCR5, respectively
    Kessler, Naama
    Akabayov, Sabine R.
    Cohen, Leah S.
    Scherf, Tali
    Naider, Fred
    Anglister, Jacob
    FEBS JOURNAL, 2024, 291 (03) : 458 - 476